Edwards Lifesciences (EW) to Release Quarterly Earnings on Thursday

Edwards Lifesciences (NYSE:EW) will be posting its quarterly earnings results after the market closes on Thursday, April 25th. Analysts expect Edwards Lifesciences to post earnings of $0.64 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter last year, the firm earned $0.64 earnings per share. The business’s revenue was up 13.3% on a year-over-year basis. On average, analysts expect Edwards Lifesciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Edwards Lifesciences Stock Performance

NYSE EW opened at $87.24 on Thursday. The business’s 50-day moving average price is $90.12 and its 200 day moving average price is $78.14. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. Edwards Lifesciences has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a market capitalization of $52.51 billion, a PE ratio of 37.93, a price-to-earnings-growth ratio of 4.42 and a beta of 1.05.

Analyst Ratings Changes

EW has been the subject of several research reports. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Morgan Stanley raised their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Mizuho lifted their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a research report on Wednesday, February 7th. Finally, Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the transaction, the vice president now directly owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the completion of the transaction, the vice president now owns 17,213 shares of the company’s stock, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock worth $17,166,254 over the last quarter. 1.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC grew its holdings in Edwards Lifesciences by 11.4% during the first quarter. Sequoia Financial Advisors LLC now owns 9,181 shares of the medical research company’s stock worth $1,081,000 after acquiring an additional 941 shares during the period. Zions Bancorporation N.A. grew its position in Edwards Lifesciences by 34.7% in the first quarter. Zions Bancorporation N.A. now owns 1,738 shares of the medical research company’s stock worth $204,000 after buying an additional 448 shares during the last quarter. Covestor Ltd increased its holdings in shares of Edwards Lifesciences by 18.2% in the first quarter. Covestor Ltd now owns 1,223 shares of the medical research company’s stock valued at $144,000 after buying an additional 188 shares in the last quarter. Mather Group LLC. lifted its position in shares of Edwards Lifesciences by 53.5% during the 1st quarter. Mather Group LLC. now owns 7,182 shares of the medical research company’s stock valued at $846,000 after acquiring an additional 2,503 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its stake in shares of Edwards Lifesciences by 3.1% during the 1st quarter. Mackenzie Financial Corp now owns 655,567 shares of the medical research company’s stock worth $77,173,000 after acquiring an additional 19,798 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.